Development of innovative antimicrobials against pathogens resistant to antimicrobials
- Funder
- European Commission · Horizon Europe
- Award amount
- €8,000,000 – €10,000,000
- Deadline
- February 17, 2027
- Eligible countries
- European Union, United Kingdom, Norway, Iceland, Switzerland, Israel, Global
Summary
Forthcoming EU call topic HORIZON-HLTH-2027-01-DISEASE-08 · HORIZON Research and Innovation Actions. Part of call HORIZON-HLTH-2027-01: Cluster 1 - Health (Single stage - 2027/1). Opens 2026-10-29; next deadline 2027-02-17. Topic page: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-DISEASE-08
Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: - The scientific and clinical communities have a better understanding of and access to new and innovative products for the treatment of antimicrobial resistant bacteria and fungi, as well as for further clinical investigation. - Candidate therapies are available to treat patients for antimicrobial resistant bacteria and fungi, increasing therapeutic options for clinical deployment in the fight against Antimicrobial Resistance (AMR).
Scope: The rapid rise of AMR presents a formidable threat to public health, challenging our ability to treat infections that were once easily managed with standard antimicrobials. As pathogens continually adapt and develop resistance to existing drugs, the efficacy of these treatments diminishes, leading to more severe and prolonged illnesses, increased healthcare costs and productivity losses, and higher mortality rates. This escalating crisis underscores an urgent need for viable therapeutic alternatives required to reduce the burden of diseases caused by antibiotic resistance. Innovative solutions are crucial to maintaining effective disease management and safeguarding public health. Proposals should pursue the development of innovative and effective antibacterial and antifungal agents, including antibody-based…
Summary as listed by the funder. Always read the full announcement for eligibility, limits and how to apply.
Read the full announcement →What European Union reviewers look for
- Most Horizon Europe calls score three criteria (the ERC uses excellence alone). Excellence: clarity and ambition of the objectives, and the soundness of the methodology.
- Impact: credible pathways to the expected outcomes, and measures to communicate and exploit results.
- Quality and efficiency of implementation: the work plan, resources and the consortium's capacity.
Read our guide: what funded applications do →
See how this call matches your research
Build a free research profile and Lantern Grants scores every open call against your work, tracks your deadlines and reminds you before they pass.
Get matched free